Aytu BioPharma, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2022. The company commercializes prescription drugs through its Rx segment and consumer health products through its Consumer Health segment. Unless otherwise noted, figures are in millions of dollars.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 |
|---|---|---|
| Net revenue | $26.3 (+14% year over year) | $53.9 (+20%) |
| Gross profit and margin | $17.3; 66% (53% prior year) | $35.3; 65% (55% prior year) |
| Operating loss | $(6.8) | $(8.4) |
| Net loss | $(6.7) | $(7.4) |
| Operating cash flow | Not separately presented | $(11.6) |
- Revenue growth was led by the Pediatric and ADHD portfolios. Consumer Health revenue was slightly lower for the quarter, which management attributed to a change in e-commerce focus and supply-chain issues.
- At December 31, cash and cash equivalents were $19.5, accounts receivable $25.5, and inventory $13.0. Current assets were $70.6 versus current liabilities of $67.2.
- Reported debt included a $7.4 short-term revolving credit balance and $14.6 of debt, net of current portion. The $15.0 Avenue term loan matures January 2025; its interest-only period was extended to January 2024. Debt is secured by substantially all company assets.
- Cash increased $0.1 from June 30, 2022. Six-month operating cash use of $11.6 was largely offset by $11.7 of financing cash inflows, including equity financing and additional revolver borrowings.
Material changes and notable items
- Six-month net loss improved from $39.4 in the prior-year period, partly because the prior period included a $19.5 goodwill impairment. Current-period results included a $2.6 impairment of NT0502 after the company decided to abandon its development.
- Research and development expense fell 55% for the six-month period as the company suspended active development of AR101 and Healight, as well as NT0502. Management said suspending AR101 and Healight is expected to avoid more than $20 of projected study costs over the next three fiscal years.
- A $3.6 six-month gain on derivative warrant liabilities (including $1.4 in the quarter) reflected fair-value remeasurement and is not operating revenue. Other expense increased, primarily due to licensing arrangements and higher debt-related costs.
- In August 2022, the company raised $10.0 gross, or approximately $9.1 net, in an offering of common stock and warrants. It also received approximately $1.5 net from at-the-market stock sales during the six months. These financings increased the share count and created potential warrant dilution.
- On January 6, 2023, after the reporting period, the company effected a 1-for-20 reverse stock split. Nasdaq confirmed on January 23 that it had regained compliance with the minimum bid-price requirement.
Outlook, risks and contingencies
- Going concern: Management stated that available working capital was insufficient to fund planned operations for the 12 months following the filing date, raising substantial doubt about the company’s ability to continue as a going concern. Plans include growing revenue, reducing expenses, raising capital or monetizing assets; success is not assured.
- Management’s stated priorities are commercial growth and achieving operating cash flow. The filing provides no specific revenue or earnings guidance.
- Management cited inflation and supply-chain disruption affecting raw materials, energy, logistics and labor, and uncertainty about continuing COVID-19 effects on demand, supply and operations.
- Potential obligations include $7.2 of remaining payments under the Tuzistra XR termination settlement; late payments may bear interest at the greater of 2.5% per month or the legal maximum. Additional product, licensing and contingent milestone obligations are described in the filing.
- The company reported ineffective disclosure controls due to a material weakness in accounting for complex warrants. Errors in warrant classification led to a restatement of the September 2022 quarter; remediation work was ongoing. The filing also describes a proposed settlement of shareholder litigation, subject to court approval, with $0.4 accrued for plaintiffs’ attorneys’ fees.
Important facts for investors to verify
- Whether the company can obtain sufficient financing or otherwise address the stated going-concern doubt, given $11.6 of operating cash use in six months.
- Whether sales growth and improved gross margins continue, and how Rx and Consumer Health performance and working-capital needs evolve.
- The potential dilution and accounting impact of outstanding warrants, including adjustments associated with the reverse split and warrant exercise-price resets.
- Progress in remediating the warrant-accounting material weakness and whether further restatements or control issues arise.
- Payment timing and total exposure under debt, the Tuzistra settlement, product agreements and contingent commitments.